Skip to main content

Table 3 Protease-activated receptor (PAR) antagonists

From: Novel agents for anti-platelet therapy

Agents

Mechanism of action

Administration

Main side effects

State

Vorapaxar

a non-peptide competitivePAR1 thrombin receptor antagonist with a high affinity and low molecular weight

oral

bleeding

unapproved

Atopaxar

PAR1 antagonist inhibiting thrombin-mediated platelet aggregation

oral

bleeding

unapproved

  1. Abbreviations: PAR:protease-activated receptor.